Member Info for Laura2022

It's ridiculous at £1.8mln value with £750k cash and c £300k + of contracts won since August and pipeline for this year alone of over £1mln

Good morning Oman

Been tiny sells for days just like in August when it then went to 3p

Good to add more here I think

Based on discussions to date, the Company does not expect to be in receipt of a capital injection or new financing into Safestyle.

 

However, the Directors are in active discussions with a shortlist of interested parties as part of the Process. These discussions focus on a sale of some or all of the Group's business and assets (a "Proposed Sale"). The Company is working with these parties towards concluding these discussions as quickly as possible

It may be useful if other genuine VAL holders do the same

I have quoted to VAL LSE and FCA rule 5c

You will not;discuss illegal or criminal activities.post any confidential or price sensitive information or that is not public knowledge.post misleading or false statements regarding the share price and performance. Such posts are deemed as market abuse, and may be reported to the appropriate authorities.

190 posts in 30 days on VAL that's 6 posts a day on a share you don't own

I have sent S Dilley details of your libelous posts qd have asked the company and the FCA to take action

I will post VALs reply here

Sienna

You are also able to contribute should you so wish

Thanks Andysell

Thanks Trench

Jim mentioned the DoseMeRx talks...surely we must hear something soon as it seems a no brained to use this verified dosing tool?

This is amazing

Well done everyone here

I would love this on some of my companies like PYC,POS VAL

Many thanks

That makes sense...I should have Checked

The date

Sorry

Many thanks Hoodier..

Am I being simple......AMT say this ..so how does this fit with THX etc

We have not selected any specific business combination target and we have not, nor has anyone on our behalf, initiated any substantive discussions, directly or indirectly, with any business combination target

We are close to the 30 days DD aren't we jwallow

Thank in advance

Where do you think PYC are in pecking order to be benefitting from Project Optimus ?

I'm assuming that given our conference appliances and publications we must be well know as being able to benefit companies who want to adhere to PO guidelines?

 From your article Trench

the quest to balance timely access to new cancer drugs with a profound understanding of patient response variability, the FDA is taking pioneering steps within the realm of oncology. Factors such as patient diversity, disease variations, and the need for individualized dosages underscore the critical importance of dosage optimization. Project Optimus, a groundbreaking initiative led by the FDA’s Oncology Center of Excellence (OCE), is at the forefront of these efforts.

Project Optimus

Project Optimus represents a transformative shift in the selection of oncology drug dosages. It brings together interdisciplinary scientists, patients, caregivers, advocacy groups, drug developers, and academia to explore innovative approaches to dose-finding and dosage optimization. Through regulatory guidance, public engagement, education, and research, this initiative actively fosters essential conversations and advancements.

The Case for Dosage Optimization

The need for dosage optimization, especially in the premarket setting, is compelling. Many new oncology drugs have required post-marketing trials to explore alternative dosages, often involving large, resource-intensive, multi-year endeavors. This highlights the possibility that some patients may have been exposed to suboptimal dosages, underscoring the urgency of our initiatives.

The PYC article published in Frontiers (see 9th May RNS) said

Project Optimus has relevance to Physiomics both in its core consulting business and its personalised oncology initiatives. In core consulting, Project Optimus encourages and some would say even mandates biotech and pharma companies to fully utilise all available non-clinical and clinical data to make informed decisions about clinical trial design and biologically effective dose. The Company believes that there is an increasing expectation that companies meeting with the FDA should have utilised mathematical modelling in support of clinical trial design and dosing decision making. The Company has first hand experience of this through the translational modelling work it has completed for multiple small and medium sized clients in recent years.

 

Looking beyond drug development, the Company sees a clear implication of Project Optimus on dosing of approved drugs in cancer. The vast majority of cancer drugs are still approved on a "one size fits all" basis with, at most, adjustments in dosing being made to account for body weight or surface area of individual patients. The Company believes that the future direction of cancer drug dosing will take into account its effect in each individual and we believe that our personalised dosing tool is a clear step towards achieving that goal.

Strange how all these new people have joined LSEin October just to post on PYC

Brighty

This is what Peter Sargent said in his PYC blog on 3rd Oct

Q: What opportunities do you see for the company?

A: “I think Physiomics certainly has an exciting future. The business has invested significantly in developing expertise and IP around its core modelling offering, with very positive client feedback and a high percentage of repeat business. With these solid foundations now built, I see an opportunity not only to scale the core business, but to build adjacent offerings in areas such as biostatistics and expand into new indications. Additionally, with continued development of our personalised medicine tools there is also the potential to significantly improve the health outcomes of cancer patients prescribed already marketed medicines

One woukd suggest ignoring new posters who have joined jut 3 weeks ago and of 24 posts 9 have been on PYC and all negative

Sad

This was a summary from last month from a poster called Stephen, which I have amended to reflect the current price of 1.5p

£2.0mln market cap with c.£750,000 cash

£1mln pipeline of deals for 2023/24 on top of the 4 or 5 won since July 2023

5 new contracts plus recommenced Merck revenues (€500,000 annually)

Hired 3 new personal to drive the business forward

Main points from the annual report below :

The Company is looking forward to a successful financial year 2024 during which it aims to achieve a new best ever level of total income, generated from its current core business and emerging biostatistics consulting offering.

Device to measure blood counts

Feedback from clinicians suggests that enabling patients to undergo these diagnostic tests in a primary care or home setting would facilitate use of our tool and as such we are actively exploring opportunities to work with Beyond Blood.

Collaborations

we are open to and continue to explore other approaches including risk sharing and collaboration. An example of this includes the risk-sharing deal with ValiRx plc announced in February 2021 for which terms have been fully disclosed and which would be triggered by the receipt by ValiRx of licensing revenues related to VAL-201

Strategic aims

expand and diversify core consulting business both through repeat business and through the acquisition of new clients;

· Supplement consulting revenues through grant funded projects, especially in the field of personalised medicine (CRUK, Innovate UK, NIHR etc);

· Expand business into related fields, starting with biostatistics. This will be the subject of further announcements later this calendar year;

· Develop new, complementary areas of business such as personalised medicine and other service offerings in drug discovery and development that can add long term value to the business.